Convergent QSAR Models for the Prediction of Cruzain Inhibitors [PDF]
ACS Omega, 2023 Chagas disease is a parasitosis caused by Trypanosoma cruzi. Cruzain, the major cysteine protease from T. cruzi, is an excellent therapeutic target in the search for antichagasic drugs. It is important in the role of cell invasion, replication, differentiation, and metabolism of the parasite.
Rafael Bello Gonçalves +4 more
doaj +4 more sources
Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay. [PDF]
PLoS Neglected Tropical Diseases, 2013 A multi-step cascade strategy using integrated ligand- and target-based virtual screening methods was developed to select a small number of compounds from the ZINC database to be evaluated for trypanocidal activity.
Helton J Wiggers +11 more
doaj +9 more sources
Impact of the Recognition Part of Dipeptidyl Nitroalkene Compounds on the Inhibition Mechanism of Cysteine Proteases Cruzain and Cathepsin L [PDF]
ACS Catalysis, 2023 Cysteine proteases (CPs) are an important class of enzymes, many of which are responsible for several human diseases. For instance, cruzain of protozoan parasite Trypanosoma cruzi is responsible for the Chagas disease, while the role of human cathepsin L
Kemel Arafet +2 more
exaly +5 more sources
The Trypanosoma cruzi protease cruzain mediates immune evasion. [PDF]
PLoS Pathogens, 2011 Trypanosoma cruzi is the causative agent of Chagas' disease. Novel chemotherapy with the drug K11777 targets the major cysteine protease cruzain and disrupts amastigote intracellular development.
Patricia S Doyle +5 more
doaj +4 more sources
Predictive Global Models of Cruzain Inhibitors with Large Chemical Coverage [PDF]
ACS Omega, 2021 Chagas disease affects 8-11 million people worldwide, most of them living in Latin America. Moreover, migratory phenomena have spread the infection beyond endemic areas. Efforts for the development of new pharmacological therapies are paramount as the pharmacological profile of the two marketed drugs currently available, nifurtimox and benznidazole ...
Jose Guadalupe Rosas-Jimenez +3 more
doaj +5 more sources
Novel cruzain inhibitors for the treatment of Chagas' disease. [PDF]
Chemical Biology & Drug Design, 2012 The protozoan parasite Trypanosoma cruzi, the etiological agent of Chagas' disease, affects millions of individuals and continues to be an important global health concern.
Arkin, Michelle R +6 more
core +6 more sources
In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. [PDF]
PLoS Neglected Tropical Diseases, 2010 Cruzain, the major cysteine protease of Trypanosoma cruzi, is an essential enzyme for the parasite life cycle and has been validated as a viable target to treat Chagas' disease.
Yen Ting Chen +6 more
doaj +4 more sources
Computational identification of uncharacterized cruzain binding sites. [PDF]
PLoS Neglected Tropical Diseases, 2010 Chagas disease, caused by the unicellular parasite Trypanosoma cruzi, claims 50,000 lives annually and is the leading cause of infectious myocarditis in the world.
Jacob D Durrant +3 more
doaj +6 more sources
Ligand-induced conformational selection predicts the selectivity of cysteine protease inhibitors. [PDF]
PLoS ONE, 2019 Cruzain, a cysteine protease of Trypanosoma cruzi, is a validated target for the treatment of Chagas disease. Due to its high similarity in three-dimensional structure with human cathepsins and their sequence identity above 70% in the active site regions,
Geraldo Rodrigues Sartori +3 more
doaj +3 more sources
Cruzain Inhibition by Terpenoids: A Molecular Docking Analysis [PDF]
Natural Product Communications, 2008 A molecular docking analysis has been carried out using monoterpene and sesquiterpene hydrocarbons and triterpenoids that have shown enzyme inhibitory activity as ligands for the cysteine protease cruzain.
Ifedayo V. Ogungbe, William N. Setzer
doaj +2 more sources